Alnylam Pharmaceuticals said this week that it has granted Sylentis, a Spanish developer of RNAi drugs, a non-exclusive option to license certain of its RNAi-related intellectual property.
According to Alnylam, the option gives Sylentis the chance to develop an siRNA-based treatment for an undisclosed glaucoma target using Alnylam's IP.
Upon execution of the option, Alnylam would receive upfront and milestone payments, and royalties on product sales. Additional terms were not disclosed.
Sylentis is currently conducting a phase I/II trial of an siRNA-based ocular hypertension drug called SYL040012. It targets adrenergic receptor beta-2 and is delivered topically to the eye.